Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...
US oncology-focused Nuvation Bio today announced non-dilutive financings of up to $250 million with Sagard Healthcare ...
Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...
The Therapeutic Goods Administration (TGA) of Australia has declined the approval of Leqembi (lecanemab) as a treatment for ...
In October 2024, the TGA made the decision not to register lecanemab (LEQEMBI) on the Australian Register of Therapeutic Goods (ARTG) for the ...
BioArctic AB's (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia ...
We are very disappointed with the TGA's decision. Foremost it is sad for all patients, caregivers and healthcare professionals in Australia who will now have to wait longer for a treatment which can ...
The EMA’s Committee for Medicinal products for Human Use (CHMP) is standing by its opinion on Leqembi (lecanemab) after the European .mission pushed back against a recommendation in November 2024 that ...
The first development is the publication of a new book, Doctored, by American investigative journalist Charles Piller, which ...
Leqembi, Biogen's Alzheimer's disease treatment developed in collaboration with Eisai, represents a significant opportunity for the company. While initial uptake has been slower than anticipated, ...
The milestone was reached as sales of Leqembi reached €200 million in Eisai fiscal year 2024 (April 2024 - Match 2025). The event entitles BioArctic to a €10 million payment. Leqembi is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback